I manage procurement for a regional hospital group. That means I oversee roughly $180,000 a year in medical supplies—wound care, surgical, infection control, you name it. I've negotiated with more vendors than I can count, documented every order in our cost tracking system, and built so many total-cost-of-ownership spreadsheets that I dream in pivot tables. Not a glamorous job, but it gives you a clear view of what actually drives healthcare spending.
Here's my professional opinion, stated as plainly as I can: most wound care purchasing is built on the wrong number. Unit price matters far less than total cost per healed wound. I've watched hospitals, clinics, and purchasing committees make this mistake for years—and I've made it myself. It took me six years and roughly 150 orders to unlearn it. Here's the data that changed my mind.
The Data That Changed My Mind
When I took this job in 2019, we used standard gauze and basic adhesive dressings. Monthly budget reports looked fantastic—our dressing costs were among the lowest in the region. I remember thinking we had this procurement thing figured out.
Then, in 2023, I finally did what I should have done from day one: I compared our wound care spending against patient outcomes, not just purchase orders. I pulled two comparable quarters—Q1 with our existing basic dressings, Q2 after we introduced Mölnlycke's Safetac-based silicone foam dressings for surgical incisions. Same patient volumes. Same procedure mix.
The unit cost per dressing jumped about 70%. I stared at that spreadsheet, certain our wound care budget was about to implode.
It didn't. Total wound care spend dropped by roughly 17%.
Why? The expensive dressings—emphasis on initially expensive—stayed in place longer. Nurses spent fewer hours on changes and re-applications. Patients reported less pain, which cut analgesic use. Post-op follow-up visits dropped. None of that showed up on the dressing purchase order line. It showed up in payroll hours, pharmacy costs, and bed availability scattered across half a dozen departmental budgets. That's the whole argument for total cost of ownership in one real-world example. (Note to self: I really should write up this methodology properly—I keep explaining it in meetings instead of just sending a doc.)
Mölnlycke Healthcare Company Overview
For anyone researching the brand: Mölnlycke (often searchable as molnlycke) is a Swedish healthcare company founded in 1849 and headquartered in Gothenburg. Roughly 8,000 employees, distribution across about 100 countries. Their focus is surgical and wound care—advanced dressings like Mepilex and Mepiform, Biogel surgical gloves, and Barrier surgical drapes and gowns.
If you're evaluating Mölnlycke wound care products specifically, the key differentiator is Safetac technology: a silicone adhesive that seals gently around the wound without sticking to the wound bed itself. If you've ever seen a patient flinch during a dressing change, you understand why that matters. Less pain, less tissue trauma, fewer changes. And every one of those clinical benefits is also a financial benefit—whether your accounting system shows it or not.
When Mölnlycke Isn't the Right Call
I'm not going to sit here and tell you Mölnlycke is the best choice for every patient in every situation. That would make me a mediocre purchaser, and it would make this article useless.
There are cases where I'd push back on spending the premium:
- Minor superficial wounds that heal in two or three days. A simple dressing does the job. Don't overspend.
- Chronic ulcers with very heavy exudate where a different dressing class—alginate or hydrofiber—may be clinically indicated. Mölnlycke makes Melgisorb for this, but use it because the assessment supports it, not because a rep suggested it.
- Facilities that won't track outcomes. Without measurement, you'll never see the return. That's not an argument against premium products; it's an argument against blind purchasing.
The honest truth: Mölnlycke earns its price in moderate-to-high acuity wound care where dressing changes are a real drain on nursing time. Outside that scope, the math gets weaker, and you should look at alternatives.
The Capital Equipment Trap
One of the biggest mistakes I've made—and watched colleagues make—is treating all medical products with the same purchasing framework. Consumables and capital equipment are different animals.
Take a surgical light. In case you've never had to buy one: it's the ceiling-mounted or mobile illumination system that provides shadow-free, color-correct lighting over the operative field. You buy one and use it for a decade plus. A fundus camera—used to photograph the retina—is in the same category. So is a dental unit, which can run anywhere from $20,000 to $60,000 depending on configuration. These are decisions about maintenance contracts, staff training, repair timelines, and depreciation, not unit cost analysis.
In 2022, I approved an OR equipment purchase based on the lowest initial quote—a bundle of surgical lights for two operating rooms. I still kick myself over that one. That lowest quote ended up costing us about $12,000 in extra service fees over the following year when the vendor's support didn't match the original promise. The same TCO discipline I'd been applying to dressings would have flagged that risk instantly. It's a lesson I now bake into every purchase above $10,000.
Handling the Skeptics
I get pushback on this from two directions. First: procurement colleagues who insist premium wound care is overhyped and real savings come from protocol discipline, not product choice. To be fair, there are facilities doing excellent wound care with basic materials because their clinical processes are exceptionally disciplined. I've seen it done. Their nurses are well-trained, their documentation is consistent, and they get strong outcomes without premium spend. That's real.
But in our hospital, the product switch and the protocol improvements had to happen together. The Safetac dressings were part of a broader change—staff education, standard assessment checklists, documentation requirements. Would we have achieved the 17% reduction with cheap dressings and those same protocol changes? Honestly? Maybe some of it. But our nurses pushed for the Mölnlycke products because they saw fewer complications and less patient discomfort. When clinical preference and cost data align like that, you lean into it.
Second: people assume I've been swayed by vendor relationships. I get the skepticism—I've sat through enough sales presentations to distrust industry claims on principle. But the peer-reviewed evidence behind Safetac is more substantial than what you usually see in this space, including randomized controlled trials and real-world evaluations of Mepilex Border published in journals like the British Journal of Nursing. Still, I'd advise any buyer to run their own pilot and track their own endpoints. That's not vendor capitulation; that's basic professional diligence.
Here's what it comes down to after six years and $180,000 in tracked spending: the most expensive wound care product you can buy is one that fails at the bedside. If Mölnlycke's technology prevents one avoidable complication or one unnecessary dressing change per patient, the higher unit price disappears into the overall cost structure. My spreadsheets say it does. Our nurses say it does. The clinical literature says it does.
For most hospital wound care programs, Mölnlycke is worth the price. Just measure your outcomes, be honest about your patient mix, and don't let any vendor—including this one—make the decision for you.
